MedTrace Logo

Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy

NCT02388984 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2017-03-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).

Conditions

Interventions

DRUG

Compound danshen dripping pills

Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.

DRUG

Placebo

Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.

Sponsors & Collaborators

  • Tasly Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Min Zhao, PhD · Tasly Group, Co. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2017-05-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02388984 on ClinicalTrials.gov